Tralokinumab联合外用糖皮质激素治疗重度特应性皮炎:ECZTRA 7 III期试验
ECZTRA 7是一项26周随机双盲安慰剂对照III期试验,纳入277例对环孢素A控制不佳或有禁忌的重度特应性皮炎成人患者。
要点
- 对环孢素A控制不佳或有禁忌的重度AD成人,tralokinumab联合TCS可显著提高第16周EASI 75应答率。
- 既往环孢素A治疗失败者中,tralokinumab组第16周EASI 75应答率亦高于安慰剂组(57% vs 41%)。
- tralokinumab联合TCS总体不良事件发生率与安慰剂联合TCS相似。
核心结论
- Tralokinumab 300 mg联合按需外用糖皮质激素对环孢素A未充分控制或有口服禁忌的重度特应性皮炎成人有效且耐受性良好。
研究设计与样本
- 26周、多中心、平行、随机、双盲、安慰剂对照III期试验,纳入277例欧洲重度特应性皮炎成人患者,按1:1随机接受皮下tralokinumab 300 mg或安慰剂每2周一次,联合按需外用糖皮质激素。
主要发现
- 第26周时EASI 75应答率较第16周进一步升高。
- 患者报告结局(包括DLQI、POEM、瘙痒和睡眠干扰)在早期即出现改善。
- 既往环孢素A治疗失败患者中,第16周tralokinumab联合TCS组EASI 75应答率为57%,安慰剂联合TCS组为41%。
- 总体不良事件发生率在治疗组间相似。
关键数值与推荐
- 主要终点为第16周EASI 75应答率。
- 既往环孢素A治疗失败亚组第16周EASI 75:tralokinumab联合TCS 57% vs 安慰剂联合TCS 41%。
临床怎么用
- 对于环孢素A未充分控制或有口服禁忌的重度特应性皮炎成人,可考虑tralokinumab 300 mg每2周皮下注射联合按需外用糖皮质激素。
- 治疗早期即可关注患者报告结局(DLQI、POEM、瘙痒、睡眠)的改善。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with severe atopic dermatitis (AD) not controlled with topical therapy have limited treatment options. Ciclosporin A (CSA) is a commonly used, broad immunosuppressant in AD, but treatment with CSA requires monitoring for potentially serious adverse effects. In a previous phase III trial, tralokinumab plus topical corticosteroids (TCS) as needed provided early and sustained improvements in AD signs and symptoms. OBJECTIVES: To evaluate the efficacy and safety of tralokinumab plus TCS in adult patients with severe AD whose disease was not adequately controlled with CSA or who had contraindications to oral CSA. METHODS: In this 26-week, multicentre, parallel, randomized, double-blind, placebo-controlled, phase III trial, European adults with severe AD were randomized 1 : 1 to subcutaneous tralokinumab 300 mg or placebo every 2 weeks plus TCS as needed. The primary endpoint was a 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16. RESULTS: In total, 277 patients were randomized. At week 16, more patients treated with tralokinumab plus TCS vs. placebo plus TCS achieved EASI 75 [64·2% vs. 50·5%; difference 14·1% (95% confidence interval 2·5-25·7); P = 0·018], which increased further up to week 26. Improvements in AD severity were accompanied by early improvements in patient-reported outcomes, including Dermatology Life Quality Index, Patient-Oriented Eczema Measure, pruritus and sleep interference. Tralokinumab plus TCS also showed a higher EASI75 response at week 16 among patients who had previously failed CSA therapy vs. placebo plus TCS (57% vs. 41%). The overall incidence of adverse events was similar between treatment arms. CONCLUSIONS: Tralokinumab 300 mg plus TCS as needed was effective and well tolerated in patients with severe AD whose disease was not adequately controlled with CSA or who had contraindications to oral CSA.
引用
- Gutermuth J, Pink AE, Worm M, et al. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2021. PMID: 34698371. doi:10.1111/bjd.20832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。